NCT04259359

Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 266 (estimated)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Venom immunotherapy (VIT) is an established treatment for Hymenoptera venom allergy and provides long-term protection from further generalized reactions in almost all patients. However, it is still unclear why bee VIT is less effective than vespid VIT. The preliminary data show that not only predominant Api m 10 sensitization but also other predominant sensitizations may be relevant as risk factors for treatment failure. Interestingly, all patients with a predominant Api m 10 sensitization who received bee VIT with a venom preparation with a supposed lack of Api m 10 tolerated sting challenges. Therefore, a multicenter study with a sufficient number of patients with treatment failure is urgently required, to clarify if predominant sensitization to a bee venom allergen is a risk factor for treatment failure. If predominant sensitization is a risk factor and caused by underrepresented components in bee venom preparations used for VIT, bee venom preparations may be optimized in the future and patients would benefit from a more effective VIT.

Conditions

• Bee Venom Allergy

Interventions

Type	Name	Description
DRUG	Insect Venom	Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.

Timeline

• Start date: 2019-05-02
• Primary completion: 2025-12-01
• Completion: 2026-03-01
• First posted: 2020-02-06
• Last updated: 2025-12-08

Locations

3 sites across 3 countries: Austria, Germany, Spain